Shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) received an average recommendation of “Hold” from the ten brokerages that currently cover the company, reports MarketBeat Ratings. One analyst rated the stock with a sell rating, five assigned a hold rating and three issued a buy rating on the company. The 12-month average target price among brokerages that have covered the stock over the past year is $10.17.
A number of equity research analysts have weighed in on the company recently. Piper Sandler downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered its price target for the company from $11.00 to $7.00 in a Wednesday 4 research report may. UBS Group began covering shares of Teva Pharmaceutical Industries in a Monday, June 13 report. They issued a “neutral” rating and a $10.00 price target on the stock. Sanford C. Bernstein upgraded Teva Pharmaceutical Industries from a “market performance” rating to an “outperform” rating and set a price target of $11.00 for the company in a Friday, March 25 research note. . Barclays upgraded Teva Pharmaceutical Industries from an ‘equal weight’ rating to an ‘overweight’ rating and raised its price target for the stock from $11.00 to $13.00 in a Tuesday research note April 5. Finally, Bank of America upgraded shares of Teva Pharmaceutical Industries from an “underperforming” rating to a “neutral” rating and set a target price of $9.00 for the company in a Tuesday 17 research note. may.
Shares of Teva Pharmaceutical Industries opened at $7.89 on Friday. Teva Pharmaceutical Industries has a 12-month low of $7.23 and a 12-month high of $10.50. The company has a current ratio of 1.07, a quick ratio of 0.73 and a debt ratio of 2.03. The company has a 50-day moving average price of $8.31 and a 200-day moving average price of $8.51. The company has a market capitalization of $8.71 billion, a PE ratio of -14.35, a growth price-earnings ratio of 0.99 and a beta of 1.22.
Teva Pharmaceutical Industries (NYSE:TEVA- Get a rating) last released its quarterly results on Tuesday, May 3. The company reported EPS of $0.53 for the quarter, meeting analyst consensus estimates of $0.53. The company posted revenue of $3.66 billion for the quarter, versus $3.75 billion expected by analysts. Teva Pharmaceutical Industries recorded a negative net margin of 3.95% and a positive return on equity of 24.04%. The company’s revenue for the quarter was down 8.1% year over year. In the same period a year earlier, the company posted earnings per share of $0.60. As a group, sell-side analysts expect Teva Pharmaceutical Industries to post earnings per share of 2.39 for the current fiscal year.
In related news, VP Hafrun Fridriksdottir sold 130,000 shares of the company in a transaction dated Tuesday, May 17. The shares were sold at an average price of $8.22, for a total transaction of $1,068,600.00. Following the completion of the sale, the vice president now owns 1,387 shares of the company, valued at approximately $11,401.14. The sale was disclosed in a filing with the SEC, accessible via this hyperlink. 0.82% of the shares are held by insiders.
A number of large investors have recently bought and sold shares of the company. Red Cedar Capital LLC increased its stake in shares of Teva Pharmaceutical Industries by 0.7% in the fourth quarter. Red Cedar Capital LLC now owns 185,920 shares of the company valued at $1,489,000 after purchasing an additional 1,250 shares in the last quarter. National Bank of Canada FI increased its stake in shares of Teva Pharmaceutical Industries by 1.3% in the 1st quarter. National Bank of Canada FI now owns 109,526 shares of the company valued at $1,025,000 after acquiring an additional 1,392 shares during the period. Morningstar Investment Services LLC increased its stake in Teva Pharmaceutical Industries by 5.5% during the first quarter. Morningstar Investment Services LLC now owns 26,631 shares of the company worth $245,000 after buying 1,395 additional shares in the last quarter. Koshinski Asset Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 61.6% in the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company valued at $32,000 after buying an additional 1,500 shares last quarter. Finally, Ensign Peak Advisors Inc increased its stake in Teva Pharmaceutical Industries by 3.4% during the 4th quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company valued at $367,000 after acquiring an additional 1,500 shares during the period. Institutional investors hold 45.79% of the company’s shares.
About Teva Pharmaceutical Industries (Get a rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Teva Pharmaceutical Industries right now?
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Teva Pharmaceutical Industries was not on the list.
Although Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here